Teclistamab, Talquetamab and Myeloma Bispecifics

Each one is a single molecule with two grips. One end binds a marker on the myeloma cell — BCMA or GPRC5D. The other end binds CD3 on the patient’s own T cell. Held side by side, the T cell recognises the myeloma cell and destroys it. The antibody itself kills nothing.

That is what “bispecific” means here: two binding ends, two different targets, one purpose. The formal class name is a T-cell engager. It is the same principle behind blinatumomab in B-cell leukaemia, applied to a different cancer and a different marker.

Families are usually told this is “a new injection”. Almost nobody says the word immunotherapy, because that word has come to mean checkpoint inhibitors for solid tumours, and these molecules work nothing like those. A checkpoint inhibitor such as pembrolizumab releases a brake on T cells that are already there. A bispecific does not release a brake. It physically drags a T cell up against a myeloma cell and holds it there. Both are immunotherapy. They are not interchangeable, and pembrolizumab is not used this way in myeloma.

An antibody can be put to work in three quite different ways, and the distinction matters when a treating team lists options. It can act on its own, as the anti-CD38 antibody daratumumab does. It can be used as a delivery vehicle, carrying a chemotherapy payload to a marker — that is an antibody-drug conjugate, such as sacituzumab govitecan. Or it can be built with a second grip and used to recruit T cells, which is what the medicines on this page do.

Which marker a drug acts on is not a technical footnote. Teclistamab and elranatamab both act on BCMA. Talquetamab acts on GPRC5D, a completely different protein. Myeloma that has stopped responding to a BCMA-directed medicine has not necessarily stopped carrying GPRC5D, which is why the two targets are usually discussed as separate options rather than as the same option twice.

All of these approvals sit in relapsed or refractory myeloma, in patients who have already had several previous lines of treatment. Accelerated and conditional approvals are granted on response data with confirmatory studies still running; they are a real regulatory status, not a lesser one, but they mean the evidence is still maturing. In the studies described in the US FDA approval notices, roughly six to seven in ten heavily pre-treated patients had a measurable response — a response rate, not a promise, and not a statement about how long anyone lives. The class is also moving quickly: in March 2026 the US FDA approved teclistamab in combination with subcutaneous daratumumab for relapsed or refractory myeloma.

Ask which marker the proposed medicine acts on — BCMA or GPRC5D. That single word decides which of these drugs are in the conversation now, and which one may still be available later.

Because switching on a large number of T cells at once can cause cytokine release syndrome. All three medicines therefore start with small step-up doses spread over several days rather than the full dose. The US labelling recommends monitoring in hospital around those doses, with premedication that usually includes a steroid, an antihistamine and paracetamol.

This is the part families are rarely prepared for. The word “injection” suggests a five-minute visit. What the first fortnight actually looks like is a short admission, a graded sequence of doses, and observation between them — and then, once that phase is complete, an ordinary weekly injection in day care. The intensity is front-loaded by design.

1. Screening before the first dose. Infection screen, blood counts, immunoglobulin levels, and a review of hepatitis and tuberculosis status. Neurological history and any seizure history are noted.
2. Step-up dose one. A small fraction of the full dose, given with premedication and observation.
3. Step-up dose two. A larger fraction, two to four days later, again with observation. Some schedules use a third step.
4. The first full dose. Given with the same monitoring. The US labelling recommends admission around each step-up dose and the first treatment dose.
5. Weekly injections after that. Once the step-up phase is complete the injection is usually given as day care, with a review before each dose.
6. A longer interval later. Some schedules move to an injection every two weeks after about six months in patients with a sustained response, which cuts the number of hospital trips.
7. Restart after a gap. If treatment is interrupted beyond a defined interval, the step-up sequence has to be repeated from the beginning. This is not optional, and it catches families out.

Two practical consequences follow, and both are worth settling before the first dose rather than during it. The family needs to be within reach of the treating unit for the first two to three weeks, because the visits are close together and an overnight stay may be needed more than once. And a missed dose is not a small matter: a gap can send the whole schedule back to step one, with another admission attached to it.

Ask three things at the planning stage: how many nights in hospital, over how many days, and what happens if a weekly dose is missed. Those answers shape the first month far more than anything else about the medicine.

Three stand out. Cytokine release syndrome, usually in the first days and usually mild to moderate. Serious infection, because these medicines strip healthy antibody-producing cells along with the myeloma. And neurological effects. Talquetamab adds taste, mouth, skin and nail changes that the BCMA-directed drugs do not.

Cytokine release syndrome and neurological toxicity are boxed warnings on all of these medicines. That sounds alarming and is meant to. In practice it is the reason the step-up schedule and the monitoring exist, and both events are recognised and managed rather than waited out.

The infection risk is the one that is most often underestimated, because it is not dramatic. BCMA-directed treatment reduces the healthy plasma cells that make antibodies, so immunoglobulin levels fall and stay low for as long as treatment continues. Preventive medicines and immunoglobulin replacement are a routine part of the plan, not a sign that something has gone wrong. A temperature of 38 °C or more during treatment needs same-day review at the treating unit or the nearest emergency department, whatever else is going on.

Talquetamab’s taste and mouth effects deserve naming in advance rather than being discovered. GPRC5D is present on some healthy tissue as well as on myeloma cells, which is why the taste buds, skin and nails are affected. It is not a sign the disease is worsening, it is dose-related, and it is one of the main reasons a two-weekly schedule is chosen.

Ask for immunoglobulin levels by name, and ask what the plan is if they fall. It is a routine, answerable question, and the answer often changes how the next six months feel.

Almost everyone with cancer, including almost everyone reading about immunotherapy. These medicines act only on markers carried by myeloma cells. Multiple myeloma is the only approved indication, and within myeloma the approvals cover disease that has returned or stopped responding after several previous lines of treatment.

They are not a treatment for solid tumours — breast, lung, colorectal, prostate, head and neck, cervical or ovarian cancer. They are not used in leukaemia, and they are not the bispecifics used in lymphoma: those are built against CD20 and are different molecules with different schedules, set out in glofitamab, mosunetuzumab and epcoritamab in lymphoma. And they are not an alternative to a checkpoint inhibitor, which acts on a different part of the immune system entirely.

Inside myeloma itself they are not for everyone either. They are not approved for newly diagnosed disease, where the standard sequence of treatment comes first; use earlier than that belongs in a clinical trial rather than in routine care. They are not started during an active, uncontrolled infection, and the plan is usually delayed rather than pushed through. A history of significant neurological disease or of seizures is weighed carefully, because neurological toxicity is a boxed warning. Pregnancy, contraception and breastfeeding need an explicit conversation before the first dose. Driving is out through the step-up phase. And frailty matters in a practical sense: the first weeks involve repeated hospital visits and possibly overnight stays, and a patient who cannot make those visits safely cannot start on this schedule.

There is also an access exclusion that deserves saying plainly rather than being discovered three months in. Where a molecule is not marketed in India, it can realistically be considered only if there is a workable import route and a realistic way to fund an open-ended course. These medicines are not given for a fixed number of cycles; they continue for as long as they keep working. A treatment that stops halfway because the next shipment did not arrive, or because the money ran out at month four, is worse than one that never started.

Asking a haematologist whether a bispecific is an option after several lines of myeloma treatment is a reasonable question. Asking for one because it is described as immunotherapy, in a cancer that carries neither BCMA nor GPRC5D, is not.

Partly, and the answer differs by molecule. Elranatamab was reported launched in India by Pfizer as Elduxio in June 2026. Teclistamab appears in a CDSCO import-and-marketing permission list published in 2023 and is listed by Indian speciality pharmacies. Talquetamab’s Indian registration is not confirmed.

This is the single most useful thing to get right, and it is also the thing most likely to be out of date. Ask about a named brand, not about the class, and confirm the answer through the treating hospital rather than through a website that sells the medicine.

Named-patient import is a real and legitimate pathway, not a workaround. In outline: the treating haematologist documents why no marketed alternative suits this patient; the hospital or a licensed importer applies for the CDSCO permit — Form 12A covers small quantities imported for a named patient’s personal use, with Form 12B and a CDEC used on the licensed-importer route; and the medicine is shipped under cold chain with its import documentation. The paperwork is why the timeline runs in weeks.

Four documents are worth insisting on in writing before any money moves, for any imported biologic: the CDSCO permit reference, the bill of entry and invoice, the batch number with the manufacturer named, and the cold-chain record from despatch to delivery. Anything without that trail should be refused. The reasoning is set out in more detail in the guidance on counterfeit immunotherapy medicines in India and on cold chain and storage.

Regulatory status changes, and it has changed twice in this class in the last two years. Confirm the current position for a named brand against CDSCO records through the treating hospital, and treat the date on this page as the limit of what it can tell you.

Same idea, very different logistics. CAR-T re-engineers the patient’s own T cells once, in a laboratory, and returns them as a single infusion. A bispecific is manufactured already, comes out of a fridge, and is injected repeatedly for as long as it works. There is no cell collection and no manufacturing wait.

CION Cancer Clinics does not provide CAR-T or any cell therapy. Where a haematologist raises it, the role here is referral and orientation only — the treatment itself happens at a licensed centre. Where BCMA CAR-T actually stands in India sets out the current position for myeloma specifically, and the CAR-T referral pathway in India describes how a referral runs.

The practical difference is the wait and the ceiling on where treatment can happen. A bispecific can be started in a unit that has never made a cell product, from stock, in the week it is decided on. That is the whole reason the class has grown as fast as it has, and for a patient whose myeloma is moving, weeks matter.

It is not the smaller commitment, though, and it is worth being clear-eyed about that. CAR-T is one event with a long tail of monitoring. A bispecific is an open-ended course: injections that continue indefinitely, review before each dose, and an infection risk that runs for as long as the treatment does. Which of the two is even on the table is decided by the disease, by what has already been used, and by what is actually obtainable — not by which one sounds more advanced.

There is no single figure, and no Indian maximum retail price for a molecule that is not marketed here. Reported Indian speciality-pharmacy listings in August 2026 put a 153 mg teclistamab vial at roughly ₹2.7 lakh against a listed MRP near ₹3.4 lakh. Indian pricing for elranatamab was not disclosed at launch.

The most useful document a family can obtain here is a written estimate for the first three months — the step-up admission, the weekly doses, the monitoring, and immunoglobulin replacement if it is likely — rather than a price per vial. Where the medicine is imported, the drug line and the hospital line come from two different organisations, and a figure quoted by one of them is routinely mistaken for the total.

On insurance and government schemes, expect to have to ask rather than assume. Scheme packages and many policies are written around medicines approved and marketed in India, so an imported unapproved product commonly falls outside them for exactly that reason, while a locally launched brand may be treated differently. Confirm the position in writing before the first dose, not after it. Immunotherapy Medicines Explained sets out how approval status, brand and reimbursement interact across this whole group of drugs.

• Glofitamab, Mosunetuzumab and Epcoritamab in Lymphoma — the same idea against CD20, in a different blood cancer.
• BCMA CAR-T for Myeloma in India — where cell therapy for myeloma actually stands here.
• Daratumumab — the anti-CD38 antibody most patients meet well before a bispecific is discussed.
• Sacituzumab Govitecan in Triple-Negative Breast Cancer — an antibody used as a delivery vehicle rather than a T-cell engager.
• Pembrolizumab (Keytruda): What It Is and How It Is Used — how a checkpoint inhibitor differs from everything on this page.
• Immunotherapy Medicines Explained — the index of antibodies, checkpoint inhibitors and biosimilars.
• Immunotherapy at a glance — what this family of treatments does, and what it does not.

Editorial information about prescription-only medicines — not an offer, a price list, or a recommendation to use any named product, and no comparative quality claim between manufacturers. Clinical statements follow the product labelling and the published approval notices of the US FDA, the European Medicines Agency and CDSCO; approval, availability and pricing statements are indicative, dated to August 2026, and regulatory status can change. Whether any of these medicines applies to a particular patient, and at what point in treatment, is a decision for the treating haematologist-oncologist.